Document is current
Any future updates will be listed below
-
Authors
Spaas, Mathieu
Sundahl, Nora
Hulstaert, Eva
Kruse, Vibeke
Rottey, Sylvie
De Maeseneer, Daan
Surmont, Veerle
Meireson, Annabel
Brochez, Lieve
Reynders, Dries
Goetghebeur, Els
Van den Begin, Robbe
Van Gestel, Dirk
Renard, Vincent
Dirix, Piet
Mestdagh, Pieter
Ost, Piet
-
Funding
Funding for this research was provided by:
Kom op tegen Kanker (KW/1892/RTH/003/013)
Varian Medical Systems (KW/1992/RTH/008/013)
- License Information
-
More Information
Article History
Received: 26 October 2020
Accepted: 23 March 2021
First Online: 7 May 2021
Declarations
:
: This study has received ethical approval from the Ghent University Hospital Ethics committee (EC2017/1678) in February 2018. All patients will give their written informed consent before inclusion. This will be obtained from each participant by the radiation oncologist.
: Not applicable.
: MS has received travel grants from Astellas, unrelated to this research project. NS has received travel grants from Merck Sharpe & Dohme, Astellas, Bayer and Bristol-Myers Squibb, all unrelated to this research project. VK has served on advisory boards for and received travel grants from Bristol-Myers Squibb and Merck Sharpe & Dohme, unrelated to this research project. SR has received honoraria from Bristol-Myers Squibb, Merck and Roche, as well as grant funding from Merck and Roche, all unrelated to this research project. DVG has received consultancy fees from Sanofi, Merck, Takeda, Novartis. PD has received honoraria from Bayer, Ferring Pharmaceuticals, Ipsen, Janssen, Astellas, as well as grant funding from Janssen, all unrelated to this research project. PO has received research funding from Merck and Varian, has consulted for Ferring Pharmaceuticals, Bayer AG and Janssen, and has received travel grants from Ipsen and Ferring Pharmaceuticals, all unrelated to this research project. The other authors declare that they have no competing interests.
